Industry News (Adenoviral Vectors)

Improved Vectors for In Vivo Gene Therapy Engineered

Published in AIDS Weekly, November 20th, 1995

Cell Genesys, Inc., Foster City, California, reported that a team of its scientists has successfully engineered novel adenoviral vectors which are capable of long term gene expression and which can avoid the toxicities seen with earlier versions of these vectors described by others.

Adenoviral vectors are currently being used to deliver genes directly to patients as a form of in vivo gene therapy for such life threatening diseases as cystic fibrosis and cancer. The work was carried out by a team of scientists at Cell Genesys led by Mitchell Finer, Ph.D. and was reported at the Fourth International Conference on Gene Therapy of Cancer in San Diego, California.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-11-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry